Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bridgebio Pharma Inc
(NQ:
BBIO
)
31.04
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
August 18, 2022
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 10, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
July 26, 2022
Via
Benzinga
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
June 22, 2022
Via
Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
May 26, 2022
Via
Benzinga
Where BridgeBio Pharma Stands With Analysts
May 06, 2022
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
July 26, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
May 05, 2022
Via
Benzinga
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
April 04, 2022
BridgeBio Pharma Inc (NASDAQ: BBIO)
Via
Benzinga
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
June 22, 2022
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
May 31, 2022
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.
Via
Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
May 24, 2022
Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
May 20, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
May 12, 2022
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
March 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 6 Analyst Ratings Have To Say About BridgeBio Pharma
March 16, 2022
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Where BridgeBio Pharma Stands With Analysts
March 16, 2022
Analysts have provided the following ratings for BridgeBio Pharma (NASDAQ:BBIO) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
March 14, 2022
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group...
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder
March 08, 2022
BridgeBio Pharma Inc (NASDAQ: BBIO) has agreed to sell Nulibry (fosdenopterin) for injection to Sentynl Therapeutics Inc, owned by Zydus Lifesciences Ltd....
Via
Benzinga
Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications
March 03, 2022
Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have updated their existing strategic collaboration to develop, manufacture, and commercialize...
Via
Benzinga
Insider Weekends: Co-Founder Of EverQuote Acquires $1.45 Million Worth Of Stock
January 09, 2022
Reviewing the list of companies that were at a new 52 week high and the ones that had hit a fresh 52 week low last week, I was struck by just how many of the companies in the 52...
Via
Benzinga
BZ Chart Of The Day: BridgeBio Pharma Teaches Traders Harsh Lesson
January 05, 2022
After a huge move lower, shares of BridgeBio Pharma, Inc. (NASDAQ:
Via
Benzinga
40 Biggest Movers From Friday
January 03, 2022
Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.